Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial.

Details

Language :

English

ISSN :

0732183X

Volume :

41

Issue :

32

Database :

Supplemental Index

Journal :

Journal of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

173469384

Full Text :

https://doi.org/10.1200/JCO.23.00790